Skip to content

    Global Health

    MEDANTAGood
    Healthcare·5 Feb 2025
    Management Summary

    Global Health (Medanta) delivered a steady Q3 FY25, characterized by strong volume growth and significant margin outperformance in its developing hospitals. While matured hospitals grew at 10%, the Lucknow and Patna units are scaling rapidly with 64% occupancy. Management is aggressively expanding capacity with a 1,000-bed addition planned over the next two years and a long-term ₹3,000 crore capex plan for greenfield projects in Mumbai and Delhi.

    Highlights

    8
    • Total Income reached ₹959.5 crores, representing a 12% YoY growth.

    • EBITDA for the quarter stood at ₹253.8 crores, up 8% YoY with a margin of 27.5%.

    • Profit After Tax (PAT) grew 16% YoY to ₹142.9 crores, with PAT margins improving to 14.9%.

    • Inpatient volumes increased by 13% YoY to 44,856; Outpatient volumes grew by 9% YoY.

    • Average Revenue Per Occupied Bed (ARPOB) for the group was ₹61,307, a marginal 1.3% increase.

    • Developing hospitals (Lucknow and Patna) reported a strong EBITDA margin of approximately 33.8%.

    • International patient revenue grew 14% YoY to ₹54.1 crores, contributing ~6% of total revenue.

    • Board approved a new 110-bed hospital lease in Ranchi with a total investment under ₹50 crores.

    Concerns

    1
    • Legal/Regulatory delays in Indore

    What Changed2

    vs Q4 FY25

    Guidance items6 → 5 (-1)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Total Income₹959.5 Cr+12%YoY
    2. 02EBITDA₹253.8 Cr+8%YoY
    3. 03EBITDA Margin27.5%
    4. 04PAT₹142.9 Cr+16%YoY
    5. 05ARPOB₹61,307+1.3%YoY

    Segment breakdown

    • Matured Hospitals (Gurgaon, Indore, Ranchi)₹646.6 Cr68.3%
    • Developing Hospitals (Lucknow, Patna)₹300.4 Cr31.7%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Capacity
    Noida Hospital Operational Timeline
    3-6 months
    High
    Capacity
    Planned Bed Additions
    1,000 beds
    High
    Capacity
    Greenfield Capacity
    1,600 beds
    Medium
    Capex
    Total Capex
    ₹3,000 crores
    High
    Other
    Ranchi Expansion Investment
    < ₹50 crores
    High

    Risks & concerns

    5
    RiskSeverity

    Legal/Regulatory delays in Indore

    The Indore project is currently on hold and subjudice due to legal challenges.Management acknowledged

    high

    Geopolitical turmoil in Bangladesh

    Turmoil in Bangladesh has historically impacted international patient flow to India, though Medanta is seeing offsets from other regions.Both acknowledged

    medium

    Pollution-related construction stoppages in Delhi NCR

    Construction at South Delhi has been stopped and started 6-7 times due to pollution regulations.Management acknowledged

    medium

    Competitive intensity in Noida

    Management believes entry of competitors like Max Healthcare in Noida will help build the medical ecosystem rather than hurt Medanta.Analyst downplayed

    low

    Areas of Evasion(1)

    • Specific EBITDA break-even timeline for Noida (refused to 'hazard a guess').

    Q&A highlights

    3

    “Occupancy as a percentage may be a little inappropriate to just look at as a single metric just because of the fact that the denominator keeps changing with respect to the bed additions.”

    Clarifies that while occupancy % might fluctuate due to rapid bed additions, absolute volume (occupied bed days) is the true growth driver.

    asked by Amey Chalke

    2 min read5 chapters

    Detailed Narrative

    01

    Developing Hospitals Outperform Matured Units

    The developing hospitals segment, comprising Lucknow and Patna, has become a significant growth engine, reporting an EBITDA margin of ~33.8% compared to 25% for matured hospitals. This outperformance is driven by high occupancy (64%) and rapid scaling of complex procedures like robotic surgery in Lucknow. Management noted that while ARPOB in these units (₹52,502) is lower than matured units (₹67,303), it is primarily due to the payor mix and they are actively working to reduce the Average Length of Stay (ALOS) to improve realizations.

    02

    Aggressive Capacity Expansion Pipeline

    Medanta is entering a high-growth phase with 1,000 beds planned for addition over the next two years. The 550-bed Noida facility is on track to be operational by Summer 2025, and a new 110-bed facility in Ranchi was recently approved to alleviate capacity constraints at the existing unit. Furthermore, the company has a long-term pipeline of 1,600 beds across Mumbai Oshiwara, Pitampura, and South Delhi, supported by a ₹3,000 crore capex plan over 3-4 years.

    03

    International Patient Dynamics and Bangladesh Headwinds

    International patient revenue grew 14% YoY to ₹54.1 crores, now making up 6% of total group revenue. Management acknowledged that while the traditional flow from Bangladesh has been hampered by local turmoil, they are successfully diversifying into African and CIS markets. They expect the upcoming Noida facility to become a major hub for international patients due to its strategic location.

    04

    Operational Efficiency and Payor Mix Strategy

    The group's ARPOB growth was a modest 1.3%, impacted by a higher proportion of scheme and PPP patients in Patna and Lucknow. However, management emphasized that realization per patient remains healthy and the focus is on volume-led growth. They have not taken a tariff increase in Lucknow for five years or Patna for three years, suggesting significant latent pricing power that could be exercised in the future.

    05

    Navigating Regulatory and Legal Hurdles

    Expansion is not without challenges; the Indore project remains stalled due to subjudice legal matters, and the South Delhi project has faced multiple stoppages due to pollution-related construction bans in the NCR region. Management is exploring alternative options for Indore while remaining committed to the site if legal issues resolve. In South Delhi, soil testing has commenced, signaling a move toward active construction.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.